SUNCT syndrome is one of the rarest primary headache disorders known to medicine. Its estimated prevalence is 1 to 9 per 100,000 people, and its incidence (new cases per year) sits around 1.2 per 100,000. Among all headache patients seen in specialty clinics, SUNCT and its close relative SUNA together account for only about 0.3% of cases. To put that in perspective, cluster headache, itself considered uncommon, affects roughly 50 to 100 people per 100,000, making SUNCT at least ten times rarer.
What SUNCT Syndrome Actually Is
SUNCT stands for Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing. That mouthful of a name describes exactly what happens: brief, intense stabs of pain on one side of the head, accompanied by a red, watery eye on the same side. The attacks are severe but short, typically lasting seconds to a few minutes each. They can strike dozens or even hundreds of times per day during active periods.
SUNCT belongs to a family of headache disorders called trigeminal autonomic cephalalgias, which also includes cluster headache and paroxysmal hemicrania. Within that family, SUNCT is the least common member by a wide margin.
Who Gets It
Early case reviews found a strong male predominance, with men outnumbering women roughly 4 to 1, and a mean age of onset around 51. More recent data from larger studies, including a 76-patient Chinese cohort, have painted a somewhat different picture, showing a slight female predominance and a younger average onset in the late 30s to early 40s. These differences likely reflect better recognition and diagnosis over time rather than a true shift in who develops the condition.
Regardless of sex, most people with SUNCT wait years for a correct diagnosis. One multicenter study found the average delay between symptom onset and diagnosis was 2.5 to 3 years, though some patients waited over 20 years. The condition is frequently misdiagnosed as trigeminal neuralgia because the two share similar short, stabbing pain patterns on one side of the face.
Why It Goes Unrecognized
Several factors keep SUNCT hidden. The attacks are so brief that they can be over before a patient can even describe what happened. Many doctors, including neurologists, may never encounter a case in their careers. And because SUNCT overlaps with trigeminal neuralgia and other facial pain conditions, patients often receive the wrong label and the wrong treatment for years.
The formal diagnostic criteria require attacks of one-sided head pain with both eye redness and tearing on the same side. Episodes must occur in bouts lasting at least 7 days, separated by pain-free windows of 3 months or more. That episodic pattern can make the condition even harder to pin down, since symptoms disappear for months at a time and may not be present during a clinic visit.
SUNCT vs. SUNA
SUNCT has a close sibling called SUNA (Short-lasting Unilateral Neuralgiform headache attacks with cranial Autonomic symptoms). The difference is subtle: SUNCT requires both eye redness and tearing, while SUNA requires only one of those features, or may involve other autonomic signs like nasal congestion or eyelid swelling. SUNA appears to be slightly more common than SUNCT, but both are rare enough that they’re often studied together under the umbrella term SUNHA.
The two conditions differ in a few practical ways. SUNCT pain tends to center around the temple, while SUNA pain more often involves the top of the head. SUNA also takes slightly longer to diagnose on average, possibly because its autonomic features are less dramatic and easier to overlook.
Secondary Causes to Rule Out
Not every case of SUNCT is a standalone condition. A review of 69 reported cases with SUNCT-like symptoms found identifiable underlying causes in every one. The most common were blood vessel abnormalities pressing on nerves (about half of cases), followed by tumors (roughly a quarter), infections, inflammatory diseases, trauma, and congenital malformations. Pituitary tumors are a particularly well-known culprit.
This is why brain imaging is essential for anyone diagnosed with SUNCT. A significant number of cases that look like SUNCT turn out to have a structural cause that, once treated, can resolve the headaches entirely. The distinction between “primary” SUNCT (no identifiable cause) and “secondary” SUNCT (caused by a lesion or other condition) has real treatment implications.
How It’s Managed
Because SUNCT attacks are so short, pain medications taken during an episode don’t work fast enough to help. Standard migraine and cluster headache treatments are also largely ineffective. The first-line preventive treatment is lamotrigine, an anticonvulsant that reduces the frequency and severity of attacks. In a large prospective study with pooled data from multiple trials, about 54% of SUNCT patients responded meaningfully to lamotrigine. That’s a modest success rate, but given how few options exist, it remains the best-supported choice.
For the roughly half of patients who don’t respond, other anticonvulsants and nerve-targeting procedures are sometimes tried, though evidence for these alternatives is limited to small case series. The rarity of the condition makes large clinical trials nearly impossible to conduct.
Living With an Ultra-Rare Diagnosis
The practical reality of SUNCT goes beyond the attacks themselves. Because so few clinicians have experience with the condition, patients often cycle through multiple specialists and incorrect diagnoses before landing on the right one. The average duration of symptoms at the time of first reporting in the medical literature was 7 years, meaning most published cases had already endured the condition for the better part of a decade before their experience was formally documented.
For the roughly 6 to 7 people per 100,000 living with SUNCT at any given time, connecting with a headache specialist who has seen at least a few cases can make a meaningful difference in both diagnosis speed and treatment outcomes. Headache centers affiliated with academic medical institutions are the most likely places to find that expertise.